-
1
-
-
41349099104
-
Cancer statistics, 2008
-
10.3322/CA.2007.0010 18287387
-
A Jemal R Siegel E Ward Y Hao J Xu T Murray, et al. 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387
-
(2008)
CA Cancer J Clin
, vol.58
, Issue.2
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Murray, T.6
-
2
-
-
0036675220
-
Metastasis to bone: Causes, consequences and therapeutic opportunities
-
DOI 10.1038/nrc867
-
GR Mundy 2002 Metastasis to bone: causes, consequences and therapeutic opportunities Nat Rev Cancer 2 8 584 593 10.1038/nrc867 12154351 (Pubitemid 37328925)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.8
, pp. 584-593
-
-
Mundy, G.R.1
-
3
-
-
0032888683
-
Factors regulating the growth of metastatic cancer in bone
-
DOI 10.1677/erc.0.0060333
-
BF Boyce T Yoneda TA Guise 1999 Factors regulating the growth of metastatic cancer in bone Endocr Relat Cancer 6 3 333 347 10.1677/erc.0.0060333 10516850 (Pubitemid 29459783)
-
(1999)
Endocrine-related Cancer
, vol.6
, Issue.3
, pp. 333-347
-
-
Boyce, B.F.1
Yoneda, T.2
Guise, T.A.3
-
4
-
-
0030749321
-
Skeletal complications of malignancy
-
10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G 9362426
-
RE Coleman 1997 Skeletal complications of malignancy Cancer 80 8 Suppl 1588 1594 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2- G 9362426
-
(1997)
Cancer
, vol.80
, Issue.8 SUPPL
, pp. 1588-1594
-
-
Coleman, R.E.1
-
5
-
-
0037301981
-
Mechanisms of osteolytic bone metastases in breast carcinoma
-
10.1002/cncr.11132 12548583
-
SM Kakonen GR Mundy 2003 Mechanisms of osteolytic bone metastases in breast carcinoma Cancer 97 3 Suppl 834 839 10.1002/cncr.11132 12548583
-
(2003)
Cancer
, vol.97
, Issue.3 SUPPL
, pp. 834-839
-
-
Kakonen, S.M.1
Mundy, G.R.2
-
6
-
-
4644261592
-
Mechanisms of Bone Metastasis
-
DOI 10.1056/NEJMra030831
-
GD Roodman 2004 Mechanisms of bone metastasis N Engl J Med 350 16 1655 1664 10.1056/NEJMra030831 15084698 (Pubitemid 38501167)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.16
-
-
Roodman, G.D.1
-
7
-
-
0033888977
-
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
-
10934148
-
DL Lacey HL Tan J Lu S Kaufman G Van W Qiu, et al. 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo Am J Pathol 157 2 435 448 10934148
-
(2000)
Am J Pathol
, vol.157
, Issue.2
, pp. 435-448
-
-
Lacey, D.L.1
Tan, H.L.2
Lu, J.3
Kaufman, S.4
Van, G.5
Qiu, W.6
-
8
-
-
33846081104
-
The RANK/RANKL/OPG triad in cancer-induced bone diseases
-
DOI 10.1007/s10555-006-9021-3, Special issue on Bone Metastasis and Cancer
-
WC Dougall M Chaisson 2006 The RANK/RANKL/OPG triad in cancer-induced bone diseases Cancer Metastasis Rev 25 4 541 549 10.1007/s10555-006-9021-3 17180711 (Pubitemid 46071863)
-
(2006)
Cancer and Metastasis Reviews
, vol.25
, Issue.4
, pp. 541-549
-
-
Dougall, W.C.1
Chaisson, M.2
-
9
-
-
35448974577
-
Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
-
DOI 10.1186/1471-2407-7-148
-
C Morrissey P Kostenuik L Brown R Vessella E Corey 2007 Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases BMC Cancer 7 1 148 10.1186/1471-2407-7-148 17683568 (Pubitemid 47616436)
-
(2007)
BMC Cancer
, vol.7
, pp. 148
-
-
Morrissey, C.1
Kostenuik, P.L.2
Brown, L.G.3
Vessella, R.L.4
Corey, E.5
-
10
-
-
0037077212
-
Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix
-
DOI 10.1074/jbc.M111663200
-
SL Dallas JL Rosser GR Mundy LF Bonewald 2002 Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix J Biol Chem 277 24 21352 21360 10.1074/jbc.M111663200 11929865 (Pubitemid 34952275)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.24
, pp. 21352-21360
-
-
Dallas, S.L.1
Rosser, J.L.2
Mundy, G.R.3
Bonewald, L.F.4
-
11
-
-
0032540319
-
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
-
DOI 10.1016/S0092-8674(00)81569-X
-
DL Lacey E Timms H-L Tan MJ Kelley CR Dunstan T Burgess, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 2 165 176 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
-
(1998)
Cell
, vol.93
, Issue.2
, pp. 165-176
-
-
Lacey, D.L.1
Timms, E.2
Tan, H.-L.3
Kelley, M.J.4
Dunstan, C.R.5
Burgess, T.6
Elliott, R.7
Colombero, A.8
Elliott, G.9
Scully, S.10
Hsu, H.11
Sullivan, J.12
Hawkins, N.13
Davy, E.14
Capparelli, C.15
Eli, A.16
Qian, Y.-X.17
Kaufman, S.18
Sarosi, I.19
Shalhoub, V.20
Senaldi, G.21
Guo, J.22
Delaney, J.23
Boyle, W.J.24
more..
-
12
-
-
0036773564
-
RANK ligand is a prerequisite for cancer-associated osteolytic lesions
-
DOI 10.1002/path.1199
-
S Kitazawa R Kitazawa 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions J Pathol 198 2 228 236 10.1002/path.1199 12237883 (Pubitemid 35243881)
-
(2002)
Journal of Pathology
, vol.198
, Issue.2
, pp. 228-236
-
-
Kitazawa, S.1
Kitazawa, R.2
-
13
-
-
28544452658
-
Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system
-
10.1111/j.0105-2896.2005.00327.x 16313339
-
S Tanaka K Nakamura N Takahasi T Suda 2005 Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system Immunol Rev 208 30 49 10.1111/j.0105-2896.2005.00327.x 16313339
-
(2005)
Immunol Rev
, vol.208
, pp. 30-49
-
-
Tanaka, S.1
Nakamura, K.2
Takahasi, N.3
Suda, T.4
-
14
-
-
38749106994
-
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
-
DOI 10.1016/j.ctrv.2007.09.002, PII S0305737207001363
-
GD Roodman WC Dougall 2008 RANK ligand as a therapeutic target for bone metastases and multiple myeloma Cancer Treat Rev 34 1 92 101 10.1016/j.ctrv.2007.09.002 17964729 (Pubitemid 351181016)
-
(2008)
Cancer Treatment Reviews
, vol.34
, Issue.1
, pp. 92-101
-
-
Roodman, G.D.1
Dougall, W.C.2
-
15
-
-
0035021176
-
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
-
10.1172/JCI11685 11375413
-
J Zhang J Dai Y Qi DL Lin P Smith C Strayhorn, et al. 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 10 1235 1244 10.1172/JCI11685 11375413
-
(2001)
J Clin Invest
, vol.107
, Issue.10
, pp. 1235-1244
-
-
Zhang, J.1
Dai, J.2
Qi, Y.3
Lin, D.L.4
Smith, P.5
Strayhorn, C.6
-
16
-
-
0344844468
-
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone
-
14633717
-
J Zhang J Dai Z Yao Y Lu W Dougall ET Keller 2003 Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone Cancer Res 63 22 7883 7890 14633717
-
(2003)
Cancer Res
, vol.63
, Issue.22
, pp. 7883-7890
-
-
Zhang, J.1
Dai, J.2
Yao, Z.3
Lu, Y.4
Dougall, W.5
Keller, E.T.6
-
17
-
-
0035360265
-
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
-
11389072
-
S Morony C Capparelli I Sarosi DL Lacey CR Dunstan PJ Kostenuik 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res 61 11 4432 4436 11389072
-
(2001)
Cancer Res
, vol.61
, Issue.11
, pp. 4432-4436
-
-
Morony, S.1
Capparelli, C.2
Sarosi, I.3
Lacey, D.L.4
Dunstan, C.R.5
Kostenuik, P.J.6
-
18
-
-
48649097728
-
Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-{kappa}B ligand
-
10.1158/0008-5472.CAN-07-5889 18632634
-
TJ Wilson KC Nannuru M Futakuchi A Sadanandam RK Singh 2008 Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-{kappa}B ligand Cancer Res 68 14 5803 5811 10.1158/0008-5472.CAN-07-5889 18632634
-
(2008)
Cancer Res
, vol.68
, Issue.14
, pp. 5803-5811
-
-
Wilson, T.J.1
Nannuru, K.C.2
Futakuchi, M.3
Sadanandam, A.4
Singh, R.K.5
-
19
-
-
41949122740
-
Proteases as modulators of tumor-stromal interaction: Primary tumors to bone metastases
-
10.1016/j.bbcan.2007.11.001
-
TJ Wilson RK Singh 2008 Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases Biochimica et Biophysica Acta (BBA) Rev Cancer 1785 2 85 95 10.1016/j.bbcan.2007.11.001
-
(2008)
Biochimica et Biophysica Acta (BBA) Rev Cancer
, vol.1785
, Issue.2
, pp. 85-95
-
-
Wilson, T.J.1
Singh, R.K.2
-
20
-
-
21144438505
-
MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
-
DOI 10.1016/j.ccr.2005.04.013, PII S1535610805001248
-
CC Lynch A Hikosaka HB Acuff MD Martin N Kawai RK Singh, et al. 2005 MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL Cancer Cell 7 5 485 496 10.1016/j.ccr.2005.04.013 15894268 (Pubitemid 40719131)
-
(2005)
Cancer Cell
, vol.7
, Issue.5
, pp. 485-496
-
-
Lynch, C.C.1
Hikosaka, A.2
Acuff, H.B.3
Martin, M.D.4
Kawai, N.5
Singh, R.K.6
Vargo-Gogola, T.C.7
Begtrup, J.L.8
Peterson, T.E.9
Fingleton, B.10
Shirai, T.11
Matrisian, L.M.12
Futakuchi, M.13
-
22
-
-
0035805620
-
Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase
-
10.1074/jbc.M010741200 11278735
-
J Schlondorff L Lum CP Blobel 2001 Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase J Biol Chem 276 18 14665 14674 10.1074/jbc.M010741200 11278735
-
(2001)
J Biol Chem
, vol.276
, Issue.18
, pp. 14665-14674
-
-
Schlondorff, J.1
Lum, L.2
Blobel, C.P.3
-
23
-
-
0026503190
-
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor
-
1540948
-
CJ Aslakson FR Miller 1992 Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res 52 6 1399 1405 1540948
-
(1992)
Cancer Res
, vol.52
, Issue.6
, pp. 1399-1405
-
-
Aslakson, C.J.1
Miller, F.R.2
-
24
-
-
25444489567
-
Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival
-
DOI 10.1158/0008-5472.CAN-05-0885
-
Z Chen ML Varney MW Backora K Cowan JC Solheim JE Talmadge, et al. 2005 Down-regulation of vascular endothelial cell growth factor-C expression using small interfering RNA vectors in mammary tumors inhibits tumor lymphangiogenesis and spontaneous metastasis and enhances survival Cancer Res 65 19 9004 9011 10.1158/0008-5472.CAN-05-0885 16204074 (Pubitemid 41377392)
-
(2005)
Cancer Research
, vol.65
, Issue.19
, pp. 9004-9011
-
-
Chen, Z.1
Varney, M.L.2
Backora, M.W.3
Cowan, K.4
Solheim, J.C.5
Talmadge, J.E.6
Singh, R.K.7
-
26
-
-
0037109023
-
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein
-
12384531
-
X Huang MK Wong H Yi S Watkins AD Laird SF Wolf, et al. 2002 Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein Cancer Res 62 20 5727 5735 12384531
-
(2002)
Cancer Res
, vol.62
, Issue.20
, pp. 5727-5735
-
-
Huang, X.1
Wong, M.K.2
Yi, H.3
Watkins, S.4
Laird, A.D.5
Wolf, S.F.6
-
27
-
-
0032768313
-
A novel orthotopic model of breast cancer metastasis to bone
-
DOI 10.1023/A:1006689719505
-
M Lelekakis JM Moseley TJ Martin D Hards E Williams P Ho, et al. 1999 A novel orthotopic model of breast cancer metastasis to bone Clin Exp Metastasis 17 2 163 170 10.1023/A:1006689719505 10411109 (Pubitemid 29335443)
-
(1999)
Clinical and Experimental Metastasis
, vol.17
, Issue.2
, pp. 163-170
-
-
Lelekakis, M.1
Moseley, J.M.2
Martin, T.J.3
Hards, D.4
Williams, E.5
Ho, P.6
Lowen, D.7
Javni, J.8
Miller, F.R.9
Slavin, J.10
Anderson, R.L.11
-
29
-
-
7644227012
-
Caveolin-1 inhibits breast cancer growth and metastasis
-
DOI 10.1038/sj.onc.1208062
-
EK Sloan KL Stanley RL Anderson 2004 Caveolin-1 inhibits breast cancer growth and metastasis Oncogene 23 47 7893 7897 10.1038/sj.onc.1208062 15334058 (Pubitemid 39457039)
-
(2004)
Oncogene
, vol.23
, Issue.47
, pp. 7893-7897
-
-
Sloan, E.K.1
Stanley, K.L.2
Anderson, R.L.3
-
30
-
-
0032725711
-
Antisense oligonucleotides as a tool for gene functionalization and target validation
-
10806994
-
CF Bennett LM Cowsert 1999 Antisense oligonucleotides as a tool for gene functionalization and target validation Biochim Biophys Acta 1489 1 19 30 10806994
-
(1999)
Biochim Biophys Acta
, vol.1489
, Issue.1
, pp. 19-30
-
-
Bennett, C.F.1
Cowsert, L.M.2
-
31
-
-
0034780950
-
Drug properties of second-generation antisense oligonucleotides: How do they measure up to their predecessors?
-
SP Henry RS Geary R Yu AA Levin 2001 Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Curr Opin Invest Drugs 2 10 1444 1449
-
(2001)
Curr Opin Invest Drugs
, vol.2
, Issue.10
, pp. 1444-1449
-
-
Henry, S.P.1
Geary, R.S.2
Yu, R.3
Levin, A.A.4
-
33
-
-
33846139014
-
Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases
-
DOI 10.1007/s10555-006-9023-1, Special issue on Bone Metastasis and Cancer
-
VA Siclari TA Guise JM Chirgwin 2006 Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases Cancer Metastasis Rev 25 4 621 633 10.1007/s10555-006-9023-1 17165131 (Pubitemid 46075000)
-
(2006)
Cancer and Metastasis Reviews
, vol.25
, Issue.4
, pp. 621-633
-
-
Siclari, V.A.1
Guise, T.A.2
Chirgwin, J.M.3
-
34
-
-
30944436527
-
Mechanisms of disease: Roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis
-
DOI 10.1038/ncponc0381, PII N0381
-
JM Blair H Zhou MJ Seibel CR Dunstan 2006 Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis Nat Clin Pract Oncol 3 1 41 49 10.1038/ncponc0381 16407878 (Pubitemid 43108833)
-
(2006)
Nature Clinical Practice Oncology
, vol.3
, Issue.1
, pp. 41-49
-
-
Blair, J.M.1
Zhou, H.2
Seibel, M.J.3
Dunstan, C.R.4
-
35
-
-
22244455403
-
A mouse model of human breast cancer metastasis to human bone
-
DOI 10.1158/0008-5472.CAN-04-1408
-
C Kuperwasser S Dessain BE Bierbaum D Garnet K Sperandio GP Gauvin, et al. 2005 A mouse model of human breast cancer metastasis to human bone Cancer Res 65 14 6130 6138 10.1158/0008-5472.CAN-04-1408 16024614 (Pubitemid 40994398)
-
(2005)
Cancer Research
, vol.65
, Issue.14
, pp. 6130-6138
-
-
Kuperwasser, C.1
Dessain, S.2
Bierbaum, B.E.3
Garnet, D.4
Sperandio, K.5
Gauvin, G.P.6
Naber, S.P.7
Weinberg, R.A.8
Rosenblatt, M.9
-
36
-
-
0037302045
-
Mechanisms of tumor metastasis to the bone: Challenges and opportunities
-
DOI 10.1359/jbmr.2003.18.2.190
-
AH Reddi D Roodman C Freeman S Mohla 2003 Mechanisms of tumor metastasis to the bone: challenges and opportunities J Bone Miner Res 18 2 190 194 10.1359/jbmr.2003.18.2.190 12568395 (Pubitemid 36125910)
-
(2003)
Journal of Bone and Mineral Research
, vol.18
, Issue.2
, pp. 190-194
-
-
Reddi, A.H.1
Roodman, D.2
Freeman, C.3
Mohla, S.4
-
38
-
-
0142182080
-
Receptor activator of nuclear factor kappaB ligand (RANKL)/ osteoprotegerin (OPG) ratio is increased in severe osteolysis
-
14578201
-
E Grimaud L Soubigou S Couillaud P Coipeau A Moreau N Passuti, et al. 2003 Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis Am J Pathol 163 5 2021 2031 14578201
-
(2003)
Am J Pathol
, vol.163
, Issue.5
, pp. 2021-2031
-
-
Grimaud, E.1
Soubigou, L.2
Couillaud, S.3
Coipeau, P.4
Moreau, A.5
Passuti, N.6
-
39
-
-
0242440212
-
Serum osteoprotegerin and receptor activator of nuclear factor- κ B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer
-
DOI 10.1097/01.ju.0000094191.39574.cb
-
K Jung C Stephan A Semjonow M Lein D Schnorr SA Loening 2003 Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer J Urol 170 6 Pt 1 2302 2305 10.1097/01.ju.0000094191.39574.cb 14634401 (Pubitemid 37413980)
-
(2003)
Journal of Urology
, vol.170
, pp. 2302-2305
-
-
Jung, K.1
Stephan, C.2
Semjonow, A.3
Lein, M.4
Schnorr, D.5
Loening, S.A.6
-
40
-
-
0035496947
-
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease
-
10.1182/blood.V98.7.2269 11568016
-
C Seidel O Hjertner N Abildgaard L Heickendorff M Hjorth J Westin, et al. 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease Blood 98 7 2269 2271 10.1182/blood.V98.7.2269 11568016
-
(2001)
Blood
, vol.98
, Issue.7
, pp. 2269-2271
-
-
Seidel, C.1
Hjertner, O.2
Abildgaard, N.3
Heickendorff, L.4
Hjorth, M.5
Westin, J.6
-
41
-
-
0043245842
-
Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index
-
DOI 10.1182/blood-2003-02-0380
-
E Terpos R Szydlo JF Apperley E Hatjiharissi M Politou J Meletis, et al. 2003 Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index Blood 102 3 1064 1069 10.1182/blood-2003-02-0380 12689925 (Pubitemid 36917805)
-
(2003)
Blood
, vol.102
, Issue.3
, pp. 1064-1069
-
-
Terpos, E.1
Szydlo, R.2
Apperley, J.F.3
Hatjiharissi, E.4
Politou, M.5
Meletis, J.6
Viniou, N.7
Yataganas, X.8
Goldman, J.M.9
Rahemtulla, A.10
-
42
-
-
0026540256
-
Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone
-
10.1007/BF00133470 1451351
-
PJ Kostenuik G Singh KL Suyama FW Orr 1992 Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone Clin Exp Metastasis 10 6 411 418 10.1007/BF00133470 1451351
-
(1992)
Clin Exp Metastasis
, vol.10
, Issue.6
, pp. 411-418
-
-
Kostenuik, P.J.1
Singh, G.2
Suyama, K.L.3
Orr, F.W.4
-
43
-
-
15444365985
-
Bone turnover mediates preferential localization of prostate cancer in the skeleton
-
DOI 10.1210/en.2004-1211
-
A Schneider LM Kalikin AC Mattos ET Keller MJ Allen KJ Pienta, et al. 2005 Bone turnover mediates preferential localization of prostate cancer in the skeleton Endocrinology 146 4 1727 1736 10.1210/en.2004-1211 15637291 (Pubitemid 40396881)
-
(2005)
Endocrinology
, vol.146
, Issue.4
, pp. 1727-1736
-
-
Schneider, A.1
Kalikin, L.M.2
Mattos, A.C.3
Keller, E.T.4
Allen, M.J.5
Pienta, K.J.6
McCauley, L.K.7
-
44
-
-
19944432878
-
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
-
JE Brown RJ Cook P Major A Lipton F Saad M Smith, et al. 2005 Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors JNCI J Natl Cancer Inst 97 1 59 69
-
(2005)
JNCI J Natl Cancer Inst
, vol.97
, Issue.1
, pp. 59-69
-
-
Brown, J.E.1
Cook, R.J.2
Major, P.3
Lipton, A.4
Saad, F.5
Smith, M.6
-
45
-
-
0036468002
-
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status
-
DOI 10.1200/JCO.20.3.850
-
L Costa LM Demers A Gouveia-Oliveira J Schaller EB Costa MC de Moura, et al. 2002 Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status J Clin Oncol 20 3 850 856 10.1200/JCO.20.3.850 11821470 (Pubitemid 34111395)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.3
, pp. 850-856
-
-
Costa, L.1
Demers, L.M.2
Gouveia-Oliveira, A.3
Schaller, J.4
Costa, E.B.5
De Moura, M.C.6
Lipton, A.7
-
46
-
-
0029101805
-
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
-
7627963
-
A Sasaki BF Boyce B Story KR Wright M Chapman R Boyce, et al. 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice Cancer Res 55 16 3551 3557 7627963
-
(1995)
Cancer Res
, vol.55
, Issue.16
, pp. 3551-3557
-
-
Sasaki, A.1
Boyce, B.F.2
Story, B.3
Wright, K.R.4
Chapman, M.5
Boyce, R.6
-
47
-
-
24744468646
-
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo
-
16140935
-
G van der Pluijm I Que B Sijmons JT Buijs CWGM Lowik A Wetterwald, et al. 2005 Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo Cancer Res 65 17 7682 7690 16140935
-
(2005)
Cancer Res
, vol.65
, Issue.17
, pp. 7682-7690
-
-
Van Der Pluijm, G.1
Que, I.2
Sijmons, B.3
Buijs, J.T.4
Cwgm, L.5
Wetterwald, A.6
-
48
-
-
58249121577
-
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment
-
Buijs JT, Que I, Lowik CW, Papapoulos SE, Van der Pluijm G (2009) Inhibition of bone resorption and growth of breast cancer in the bone microenvironment. Bone 44(2):380-386
-
(2009)
Bone
, vol.44
, Issue.2
, pp. 380-386
-
-
Buijs, J.T.1
Que, I.2
Lowik, C.W.3
Papapoulos, S.E.4
Van Der Pluijm, G.5
-
49
-
-
33645080421
-
Kinetics of metastatic breast cancer cell trafficking in bone
-
10.1158/1078-0432.CCR-05-1806 16533765
-
PA Phadke RR Mercer JF Harms Y Jia AR Frost JL Jewell, et al. 2006 Kinetics of metastatic breast cancer cell trafficking in bone Clin Cancer Res 12 5 1431 1440 10.1158/1078-0432.CCR-05-1806 16533765
-
(2006)
Clin Cancer Res
, vol.12
, Issue.5
, pp. 1431-1440
-
-
Phadke, P.A.1
Mercer, R.R.2
Harms, J.F.3
Jia, Y.4
Frost, A.R.5
Jewell, J.L.6
-
50
-
-
33644666787
-
Bisphosphonates for treatment and prevention of bone metastases
-
DOI 10.1200/JCO.2005.02.9579
-
MD Michaelson MR Smith 2005 Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 23 32 8219 8224 10.1200/JCO.2005.02.9579 16278476 (Pubitemid 46211558)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.32
, pp. 8219-8224
-
-
Michaelson, M.D.1
Smith, M.R.2
-
51
-
-
9444254706
-
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
-
DOI 10.1080/02841860410032885
-
T Saarto L Vehmanen P Virkkunen C Blomqvist 2004 Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients Acta Oncol 43 7 650 656 10.1080/02841860410032885 15545185 (Pubitemid 39563937)
-
(2004)
Acta Oncologica
, vol.43
, Issue.7
, pp. 650-656
-
-
Saarto, T.1
Vehmanen, L.2
Virkkunen, P.3
Blomqvist, C.4
|